-
The Evolution of Pharma Depends on Data Integration and Application
The potential applications for this vast quantity and variety of data are nearly endless.
PAP-Q4-18-NI-001 -
The Coming of Age of Amorphous Solid Dispersions
Numerous drugs formulated as amorphous solid dispersions have been successfully commercialized.
PAP-Q4-18-CL-004 -
From Proof of Concept to Commercialization
Brammer’s vision is to be the leading CDMO for viral vector supply to cell and gene therapy innovators.
PAP-Q4-18-CL-003 -
Knowledge and Experience Equal Successful Technology Transfer
Technology transfer should result in the transfer of product and process knowledge into a new phase of the life cycle.
PAP-Q4-18-CL-008 -
A Turnkey Solution: Sourcing Equipment and Empowering Operators
We offer a turnkey solution by sourcing equipment that meets production line requirements.
PAP-Q4-18-CL-007 -
Designing Effective Facilities to Meet the Growing Demand for Oligonucleotide Drugs
An oligo drug manufacturing facility incorporates aspects of small-molecule and biologic drug facilities.
PAP-Q4-18-CL-002 -
Regulatory Spotlight: FDA Delays Enforcement of Serialization Mandate
The FDA issued new guidances regarding enforcement of the DSCSA's track and trace mandate.
PAP-Q4-18-NI-011 -
Big Data in Drug Development and Discovery
Companies that apply the data will have a competitive advantage in drug discovery and development.
PAP-Q4-18-NI-006 -
Big Data in Drug Manufacturing
To achieve cohesive data integration in drug manufacturing, systems must be aligned.
PAP-Q4-18-NI-005 -
Big Data in Drug Packaging and Distribution
The emphasis on serialization is a tangible move toward making post-market data mining more robust.
PAP-Q4-18-NI-004 -
Preparing Clinical Trial Logistics for a No-Deal Brexit
Pharmaceutical companies should prepare for Brexit by mitigating their supply chain risks.
PAP-Q4-18-CL-006 -
Drug Repositioning: Facilitating Drug Repositioning with Artificial Intelligence
Computer-based approaches are essential to enable systematic drug repositioning efforts.
PAP-Q4-18-NI-009 -
The Value of Complementary Specialized Capabilities
Continued investment in innovations that address the needs of current and next-generation therapies is essential.
PAP-Q4-18-CL-001 -
Risk Minimization with an Integrated Global Network
Collaborating with an embedded organization with an integrated, global network can facilitate access to growing markets.
PAP-Q4-18-CL-005 -
Preparative Chromatography
Servier’s InnoPreP™ technology offering appeals to mid-size pharmas who need to quickly move their project into clinical studies .
PAP-Q4-18-NI-002 -
New Drug News: Regulatory Approval Brings siRNA into the Rare Disease Toolbox
siRNA joins the other nucleic acid–based drugs entering the marketplace for the treatment of rare diseases.
PAP-Q4-18-NI-010 -
Foreign Investment: Chinese Capital Backs U.S. Biotech
Given the amount of Chinese capital and the growing interest in the segment, the market feels unlimited.
PAP-Q4-18-NI-008 -
Q: What Innovative Technologies Had the Greatest Impact on your Company this Year? What Were the Impacts?
Industry leaders discuss recent technological innovations.
PAP-Q4-18-NI-007 -
Q: Looking Forward, What New Technologies/Paradigms Do You Anticipate Having the Greatest Impact Next Year (Digitalization and Industry 4.0, Serialization, etc.)?
Industry leaders discuss forthcoming technological innovations.
PAP-Q4-18-NI-003
-
Clinical Study Explores the Efficacy of Numerous Ebola Therapies
The safety and efficacy of investigational Ebola medicines in multiple countries experiencing outbreaks will be evaluated internationally.
-
Mallinckrodt Spins off its Generics Business
The company will split into two divisions.
-
FDA Approves Roche's Tecentriq in Combination with Avastin and Chemotherapy for the Initial Treatment of People with a Specific Type of Metastatic Lung Cancer
This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with Avastin and chemotherapy helped people live significantly longer.
-
NYCEDC Grants $1M To Quentis Therapeutics For Expansion of LifeSci Space in West Harlem
This is the first grant to be distributed from $10M LifeSci NYC Expansion Fund.
-
Steps Ahead: Planning for Future Equipment Surpluses from the Point of Procurement
There are clear advantages to planning for your facility’s future explains Justin Kadis, Business Development Federal Equipment Company.
-
Modern OSD Facility Design Considerations for Operational Efficiency and Regulatory Compliance
When engineering and designing today’s OSD manufacturing facilities, the primary goal is to develop an operation that provides for the highest levels of product quality and operational efficiency, says Dave DiProspero, Associate/Director of Pharmaceutical Process Technology at CRB USA.
-
Knowledge and Experience Equal Successful Technology Transfer
Joe Szczesiul, Director of Technical Services at UPM Pharmaceuticals, outlines best practices for effective tech transfer.
-
From Proof of Concept to Commercialization
Mark Bamforth, CEO and Richard Snyder, CSO, explain how Brammer Bio is investing to support the commercial development of gene and cell therapies.
-
How to Tell If You’re Using a Quality Hard Capsule
Bahi Mahesan, Regulatory Affairs and Quality Manager for CapsCanada, explains the benefits of using a high-quality supplier for hard-shell capsules.
-
Designing a Better Single-Use Facility
With the right tool, single-use facility design can benefit from a proactive review of facility, systems, design intent and risk, explains Carl Carlson, Director, Bioprocess Design & Technology of M+W Group.
-
Investor Group Purchases 110-Acre Pharmaceutical Campus in Huntsville, Alabama
Diversified ultra-modern pharmaceutical campus with solid dosage form, liquid manufacturing filling, distribution warehouse, and vault storage. Assets are available for purchase and/or lease.
-
Histo-Scientific Research Laboratories and Vet Path Services Merge
Formation of company to meet growing demand for high-quality histopathology services in the research and pre-clinical therapeutics markets includes growth equity investment from Ampersand Capital Partners.
-
Researchers Discover Potential Cause for Alzheimer’s Disease
Scientists find that neurons in the brain can modify their own genes.
-
Pfizer’s Rituximab Biosimilar Achieves Positive Study Results
A comparative safety and efficacy study meets its primary endpoint.
-
Product and Service Concepts Driving Speed to Market
Jonathan Gilinski, Executive Director of CapsCanada explains how to accelerate timelines.
-
Death to Cleanrooms in Biopharmaceutical Manufacturing
Marc Pelletier, Ph.D., Director of CRB USA explains the benefits of closed processing.
-
Speeding Development and Reducing Costs with Analytical Quality by Design
António Ramos, Analytical Chemistry Group Leader, Process Chemistry Development and Rui Loureiro, Director of the R&D Process Chemistry at Hovione outline Quality by Design (QbD) in analytical method development.
-
Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services
Ed Scholtz, Ph.D., Vice President of R&D for UPM Pharmaceuticals explains the company's approach to formulations.
-
Aligning with Sponsors for Strategic Growth
Syed T. Husain, Chief Commercial Officer, and Catherine Hanley, Head of Marketing & Corporate Communications, Alcami, discuss the new company sponsorship.
-
WuXi Biologics Breaks Ground on Innovation Center in China
Global innovation center will integrate biologics discovery, development and clinical and commercial manufacturing.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestHard-Shell Capsule Solutions for Sensitive Compounds: A Focus on Probiotics
Dec 6, 2018 2:24:02 PM PAO-M12-18-CL-002FDA Gives Novartis Gene Replacement Therapy Application Priority Review
Dec 5, 2018 12:07:21 PM PAO-M12-18-NI-003Unilever’s Indian Subsidiary to Acquire GSK’s Consumer Nutrition Brands in India
Dec 5, 2018 11:58:17 AM PAO-M12-18-NI-002Regeneron’s Bispecific Antibody Candidate Shows Positive Results in Early Clinical Studies
Dec 5, 2018 11:56:33 AM PAO-M12-18-NI-007Cilag GmbH to Collaborate with argenx on New Treatment for AML, MDS
Dec 5, 2018 11:55:49 AM PAO-M12-18-NI-005Pfizer’s Rituximab Biosimilar Achieves Positive Study Results
Dec 5, 2018 11:54:25 AM PAO-M12-18-NI-001Steps Ahead: Planning for Future Equipment Surpluses from the Point of Procurement
Dec 5, 2018 10:58:20 AM PAO-M12-18-CL-001
TOPICS
View All TopicsPRESS RELEASES
View All-
XOSPATA® (gilteritinib) Available at Biologics by McKesson
Dec 13, 2018 5:00:00 AM -
Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering
Dec 13, 2018 5:00:00 AM -
NYCEDC Grants $1M To Quentis Therapeutics For Expansion of LifeSci Space in West Harlem
Dec 13, 2018 5:00:00 AM -
Impel NeuroPharma Closes $67.5 Million Series D Financing
Dec 12, 2018 5:00:00 AM -
Immuno-oncology Development Trends and Opportunities
Dec 12, 2018 5:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
